

CAPITOLO 6

BIBLIOGRAFIA

1. Silverthorn DU. Il rene. In *Fisiologia*. Casa Editrice Ambrosiana 2000; cap 18: 518-542.
2. Briggs JP, Kriz W, Schnermann JB. Overview of renal function and structure. In Greenberg A ed: *Primer on kidney diseases*. 3rd edition. New York, National Kidney Foundation 2001; 1: 3-9.
3. Treré D. Le neoplasie. In *Le basi patologiche delle malattie*, a cura di Cotran, Kumar, Collins. 6^a edizione. Robbins Piccin 2000; cap 8 (vol 1): 299-382.
4. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. *Am J Surg Pathol* 1982; 6: 655-663.
5. Garcia M, Jemal A, Ward EM, *et al.* *Global Cancer Facts & Figures 2007*. Atlanta, GA: American Cancer Society 2007.
6. American Cancer Society. *Cancer Facts & Figures 2010*. Atlanta, Ga: American Cancer Society 2010.
7. Grande E, Inghelmann R, Francisci S, *et al.* Regional estimates of all cancer malignancies in Italy. *Tumori* 2007; 93: 345-351.
8. Linehan WM, Bratslavsky G, Pinto PA, *et al.* Molecular diagnosis and therapy of kidney cancer. *Annu Rev Med* 2010; 61: 329-343.
9. AIRT Working Group. Italian Cancer Figure - Report 2006 - Incidence, mortality and estimates. *Epidemiologia e prevenzione* 2006; 30 Suppl 2.
10. AIRT Working Group. Italian Cancer Figure - Report 2007 - Survival. *Epidemiologia e prevenzione* 2008; 31 Suppl 1.
11. Mueller-Lisse UG, Mueller-Lisse UL. Imaging of advanced renal cell carcinoma. *World J Urol* 2010; 28: 253-261.
12. Wallace AC, Nairn RC. Renal tubular antigens in kidney tumors. *Cancer* 1972; 29: 977-981.
13. Bennington JL, Beckwith JB. Tumors of the Kidney, Renal Pelvis, and Ureter. *Atlas of Tumor Pathology*, 2nd series, fascicle 12. Washington, DC, Armed Forces Institute of Pathology 1975.
14. Weir JM, Dunn JE Jr. Smoking and mortality: a prospective study. *Cancer* 1970; 25: 105-112.
15. Kantor AF. Current concepts in the epidemiology and etiology of primary renal cell carcinoma. *J Urol* 1977; 117: 415-417.

16. La Vecchia C, Negri E, D'Avanzo B, *et al.* Smoking and renal cell carcinoma. *Cancer Res* 1990; 50: 5231-5233.
17. Dhote R, Thiounn N, Debré B, *et al.* Risk factors for adult renal cell carcinoma. *Urol Clin North Am* 2004; 31: 237-247.
18. Klinghoffer Z, Yang B, Kapoor A, *et al.* Obesity and renal cell carcinoma: epidemiology, underlying mechanisms and management considerations. *Expert Rev Anticancer Ther* 2009; 9: 975-987.
19. Theis RP, Dolwick Grieb SM, Burr D, *et al.* Smoking, environmental tobacco smoke, and risk of renal cell cancer: a population-based case-control study. *BMC Cancer* 2008; 8: 387.
20. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. *Nat Rev Urol* 2010; 7: 245-257.
21. Calle EE, Rodriguez C, Walker-Thurmond K, *et al.* Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *N Engl J Med* 2003; 348: 1625-1638.
22. Weng CJ, Chang MY, Chen YC, *et al.* Long-term online hemodiafiltration does not reduce the frequency and severity of acquired cystic kidney disease in hemodialysis patients. *Ren Fail* 2009; 31: 555-561.
23. Bonsib SM. Renal cystic diseases and renal neoplasms: a mini-review. *Clin J Am Soc Nephrol* 2009; 4: 1998-2007.
24. Stewart JH, Vajdic CM, van Leeuwen MT, *et al.* The pattern of excess cancer in dialysis and transplantation. *Nephrol Dial Transplant* 2009; 24: 3225–3231.
25. Zbar B, Lerman M. Inherited carcinomas of the kidney. *Adv Cancer Res* 1998; 75: 163-201.
26. Deming CL, Harvard BM. Tumors of the kidney. In Campbell MF, Harrison JH, ed: *Urology* (vol 2), 3rd edition. Philadelphia: WB Saunders 1970.
27. Dal Bianco M, Fulcoli V. I tumori del rene. In *Trattato di Medicina Interna*, a cura di Crepaldi G, Baritussio A. Piccin 2003; cap 253 (vol 3): 3639.
28. Glenn JF. Renal tumors. In Harrison JH, Gittes RF, Perlmutter AD, *et al.* eds: *Campbell's Urology*, 4th edition. Philadelphia: WB Saunders 1980.
29. Muto G, Moroni M. I tumori del rene. In *Trattato di Chirurgia Oncologica*, a cura di Mazzeo F, Forestieri P. Piccin 2003; cap 67 (vol 3).
30. Barbaric ZL. *Principles of Genitourinary Radiology*. 2nd edition. New York, Thieme Medical Publishers 1994; 154.

31. Kovacs G, Akhtar M, Beckwith BJ, *et al.* The Heidelberg classification of renal cell tumours. *J Pathol* 1997; 183: 131-133.
32. Lopez-Beltran A, Scarpelli M, Montironi R, *et al.* 2004 WHO Classification of the Renal Tumors of the Adults. *European Urology* 2006; 49: 798–805.
33. Brannon AR, Rathmell WK. Renal cell carcinoma: where will the state-of-the-art lead us?. *Curr Oncol Rep* 2010; 12: 193-201.
34. George S, Bukowski RM. Biomarkers in clear cell renal cell carcinoma. *Expert Rev Anticancer Ther* 2007; 7: 1737-1747.
35. Eble JN, Sauter G, Epstein JI, *et al.* WHO: Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press 2004.
36. Suzigan S, Lopez-Beltran A, Montironi R, *et al.* Multilocular cystic renal cell carcinoma: a report of 45 cases of a kidney tumor of low malignant potential. *Am J Clin Pathol* 2006; 125: 217-222.
37. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. *Mod Pathol* 1997; 10 :537-544.
38. Prasad SR, Humphrey PA, Catena JR, *et al.* Common and Uncommon Histologic Subtypes of Renal Cell Carcinoma: Imaging Spectrum with Pathologic Correlation. *Radiographics* 2006; 26: 1795-1806.
39. Zbar B, Brauch H, Talmadge C, *et al.* Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. *Nature* 1987; 327: 721–724.
40. Anglard P, Trahan E, Liu S, *et al.* Molecular and cellular characterization of human renal cell carcinoma cell lines. *Cancer Res* 1992; 52: 348-356.
41. Brooks JD, Bova GS, Marshall FF, *et al.* Tumor suppressor gene allelic loss in human renal cancers. *J Urol* 1993; 150: 1278-1283.
42. Latif F, Tory K, Gnarr J, *et al.* Identification of the von Hippel-Lindau disease tumor suppressor gene. *Science* 1993; 260: 1317-1320.
43. Neumann HP, Zbar B. Renal cysts, renal cancer and von Hippel-Lindau disease. *Kidney Int* 1997; 51: 16-26.
44. Gnarr JR, Tory K, Weng Y, *et al.* Mutations of the VHL tumour suppressor gene in renal carcinoma. *Nat Genet* 1994; 7: 85-90.
45. Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal carcinoma. *JAMA* 1995; 273: 564-570.
46. Kaelin WG Jr, Maher ER. The VHL tumour-suppressor gene paradigm. *Trends Genet* 1998; 14: 423-426.

47. Pfaffenroth EC, Linehan WM. Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. *Expert Opin Biol Ther* 2008; 8: 779-790.
48. Yao M, Shuin T, Misaki H, *et al.* Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer. *Cancer Res* 1988; 48: 6753-6757.
49. Weidner U, Peter S, Strohmeyer T, *et al.* Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma. *Cancer Res* 1990; 50: 4504-4509.
50. Oka H, Chatani Y, Hoshino R, *et al.* Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. *Cancer Res* 1995; 55: 4182-4187.
51. Sidhar SK, Clark J, Gill S, *et al.* The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. *Hum Mol Genet* 1996; 5: 1333-1338.
52. Haitel A, Wiener HG, Blaschitz U, *et al.* Biologic behavior of and p53 overexpression in multifocal renal cell carcinoma of clear cell type: an immunohistochemical study correlating grading, staging, and proliferation markers. *Cancer* 1999; 85: 1593-1598.
53. Kugler A, Hemmerlein B, Thelen P, *et al.* Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. *J Urol* 1998; 160: 1914-1918.
54. Yoshida MA, Ohyashiki K, Ochi H, *et al.* Rearrangement of chromosome 3 in renal cell carcinoma. *Cancer Genet Cytogenet* 1986; 19: 351-354.
55. Gomella LG, Sargent ER, Wade TP, *et al.* Expression of transforming growth factor alpha in normal human adult kidney and enhanced expression of transforming growth factors alpha and beta 1 in renal cell carcinoma. *Cancer Res* 1989; 49: 6972-6975.
56. Sargent ER, Gomella LG, Wade TP, *et al.* Expression of mRNA for transforming growth factors-alpha and -beta and secretion of transforming growth factor-beta by renal cell carcinoma cell lines. *Cancer Commun* 1989; 1: 317-322.
57. Fisher ER, Horvat B. Comparative ultrastructural study of so-called renal adenoma and carcinoma. *J Urol* 1972; 108: 382-386.
58. Colvin RB, Dickersin GR. Pathology of renal tumors. In Skinner DG, DeKemion JB, eds: *Genitourinary Cancer*. Philadelphia: WB Saunders 1978; 84.

59. Murphy WM. Diseases of the kidney. In Urological Pathology. Philadelphia: WB Saunders 1989; 409.
60. Kovacs G. Molecular differential pathology of renal cell tumours. Histopathology 1993; 22: 1-8.
61. Rainwater LM, Hosaka Y, Farrow GM, *et al.* Well differentiated clear cell renal carcinoma: Significance of nuclear deoxyribonucleic acid patterns studied by flow cytometry. J Urol 1987; 137: 15-20.
62. Grignon DJ, Ayala AG, el-Naggar A, *et al.* Renal cell carcinoma. A clinicopathologic and DNA flow cytometric analysis of 103 cases. Cancer 1989; 64: 2133-2140.
63. Boxer RJ, Waisman J, Lieber MM, *et al.* Non-metastatic hepatic dysfunction associated with renal carcinoma. J Urol 1978; 119: 468-471.
64. Bukowski RM. Prognostic factors for survival in metastatic renal cell carcinoma: update 2008. Cancer 2009; 115: 2273-2281.
65. Banks RE, Craven RA, Harnden P, *et al.* Key clinical issues in renal cancer: a challenge for proteomics. World J Urol 2007; 25: 537-556.
66. Volpe A, Patard JJ. Prognostic factors in renal cell carcinoma. World J Urol 2010; 28: 319-327.
67. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-1474.
68. Kidney. In Edge SB, Byrd DR, Compton CC, *et al.* eds: AJCC Cancer Staging Manual. 7th edition. New York, NY: Springer 2010; 479-489.
69. Martinez-Salamanca JI, Huang WC, Millan I, *et al.* Prognostic Impact of the 2009 UICC/AJCC TNM Staging System for Renal Cell Carcinoma with Venous Extension. Eur Urol 2010; 13.
70. Sorbellini M, Kattan MW, Snyder ME, *et al.* A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005; 173: 48-51.
71. Zisman A, Pantuck AJ, Dorey F, *et al.* Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001; 19: 1649-1657.
72. Frank I, Chevillat JC, Lohse CM, *et al.* An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on

- tumor stage, size, grade and necrosis: the SSIGN score. *J Urol* 2002; 168: 2395-2400.
73. Scoll BJ, Wong YN, Egleston BL, *et al.* Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis. *J Urol* 2009;181: 506-511.
 74. Swierzewski DJ, Swierzewski MJ, Libertino JA. Radical nephrectomy in patients with renal cell carcinoma with venous, vena caval, and atrial extension. *Am J Surg* 1994; 168: 205-209.
 75. Medeiros LJ, Gelb AB, Weiss LM. Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases. *Cancer* 1988; 61: 1639-1651.
 76. Takenawa J, Kaneko Y, Kishishita M, *et al.* Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy. *Int J Cancer* 1998; 79: 1-7.
 77. Aben KK, Luth TK, Janssen-Heijnen ML, *et al.* No improvement in renal cell carcinoma survival: a population-based study in the Netherlands. *Eur J Cancer* 2008; 44: 1701-1709.
 78. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. *J Urol* 2000; 163: 408-417.
 79. Nosadini R, Fioretto P. L'insufficienza renale cronica. In *Trattato di Medicina Interna*, a cura di Crepaldi G, Baritussio A. Piccin 2003; cap 243 (vol 3): 3443-3467.
 80. Swan SK, Keane WF. Clinical evaluation of renal function. In Greenberg A ed: *Primer on kidney diseases*. 3rd edition. New York, National Kidney Foundation 2001; 3: 25-28.
 81. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976; 16: 31-41.
 82. Levey AS, Bosch JP, Lewis JB, *et al.* A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999; 130: 461-470.
 83. Peracchi M, Corbetta S. Disordini del ricambio glicidico. In *Malattie del Sistema Endocrino e del Metabolismo*, a cura di Faglia G, 3^a edizione. McGraw-Hill 2002; cap 18: 407-447.

84. World Health Organisation Department of Noncommunicable Disease Surveillance Geneva (1999). Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation.
85. Powers AC. Diabete Mellito. In Principi di Medicina Interna, a cura di Harrison, 15^a edizione. McGraw-Hill 2002; cap 333: 2445-2477.
86. Kim HJ, Cho EH, Yoo JH, *et al.* Proteome analysis of serum from type 2 diabetics with nephropathy. J of Proteome Research 2007; 6: 735-743.
87. American Diabetes Association. Standards of Medical Care in Diabetes-2007. Diabetes Care 2007; 30 (Suppl 1): S4-S34.
88. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14.
89. Powers AC. Diabetes Mellitus. In Kasper DL, Braunwald E, Fauci AS, *et al.* eds: Harrison's Principles of Internal Medicine, 16th edition. New York: McGraw-Hill Medical Publishing Division 2005; 2152-2180.
90. US Renal Data System. USRDS 2009 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009; 232-241.
91. Seaquist ER, Goetz FC, Rich S, *et al.* Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989; 320: 1161-1165.
92. Amri K, Freund N, Duong Van Huyen JP, *et al.* Altered nephrogenesis due to maternal diabetes is associated with increased expression of IGF-II/mannose-6-phosphate receptor in the fetal kidney. Diabetes 2001; 50: 1069-1075.
93. Janssen B, Hohenadel D, Brinkkoetter P, *et al.* Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. Diabetes 2005; 54: 2320-2327.
94. Melville A, Richardson R, Lister-Sharp D, *et al.* Complications of diabetes: renal disease and promotion of self-management. Qual Health Care 2000; 9: 257-263.
95. Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 2007; 106: 26-31.
96. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 2008; 4: 39-45.

97. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. *Diabetes* 2005; 54: 1626-1634.
98. Li JJ, Kwak SJ, Jung DS, *et al.* Podocyte biology in diabetic nephropathy. *Kidney Int Suppl* 2007; 106: S36-S42.
99. Doublier S, Salvidio G, Lupia E, *et al.* Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. *Diabetes* 2003; 52: 1023-1030.
100. Hauser PV, Collino F, Bussolati B, *et al.* Nephrin and endothelial injury. *Curr Opin Nephrol Hypertens* 2009; 18: 3-8.
101. Campbell KN, Raij L, Mundel P. Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes. *Curr Diabetes Rev* 2011; 7: 3-7.
102. Pagtalunan ME, Miller PL, Jumping-Eagle S, *et al.* Podocyte loss and progressive glomerular injury in type II diabetes. *J Clin Invest* 1997; 99: 342-348.
103. Ozdemir AM, Hopfer U, Erhard P, *et al.* Processing advanced glycation end product-modified albumin by the renal proximal tubule and the early pathogenesis of diabetic nephropathy. *Ann N Y Acad Sci* 2005; 1043: 625-636.
104. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. *J Am Soc Nephrol* 2006; 17: 17-25.
105. Rao PV, Lu X, Standley M, *et al.* Proteomic identification of urinary biomarkers of diabetic nephropathy. *Diabetes Care* 2007; 30: 629-637.
106. Crawford J, Cotran RS. Il pancreas. In *Le basi patologiche delle malattie, a cura di Cotran, Kumar, Collins*. 6^a edizione. Robbins Piccin 2000; cap 20 (vol 2): 1055-1085.
107. Meerwaldt R, Links T, Zeebregts C, *et al.* The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. *Cardiovasc Diabetol* 2008; 7: 29.
108. Bierhaus A, Humpert PM, Morcos M, *et al.* Understanding RAGE, the receptor for advanced glycation end products. *J Mol Med* 2005; 83: 876-886.
109. Nguyen G, Burcklé CA, Sraer JD. Renin/prorenin-receptor biochemistry and functional significance. *Curr Hypertens Rep* 2004; 6: 129-132.
110. Ichihara A, Hayashi M, Kaneshiro Y, *et al.* Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. *J Clin Invest* 2004; 114: 1128-1135.

111. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. *J Clin Invest* 1996; 98: 1063-1068.
112. Del Vecchio L, Sitia S. Aldosterone e danno renale: implicazioni cliniche. *Giornale italiano di nefrologia* 2009; 3: 347-354.
113. Miyata K, Rahman M, Shokoji T, *et al.* Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. *J Am Soc Nephrol* 2005; 16: 2906-2912.
114. Blasi ER, Rocha R, Rudolph AE, *et al.* Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. *Kidney Int* 2003; 63: 1791-1800.
115. Ritz E, Ogata H, Orth SR. Smoking: a factor promoting onset and progression of diabetic nephropathy. *Diabetes Metab* 2000; 26: 54-63.
116. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. *Diabetes* 1983; 32: 64-78.
117. Ritz E. Pathogenesis, Clinical Manifestations, and Natural History of Diabetic Nephropathy. In Feehally J, Floege J, Johnson RJ eds: *Comprehensive Clinical Nephrology*. 3rd edition. Mosby Elsevier 2007; 5: 353-364.
118. Gall MA, Rossing P, Skott P, *et al.* Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. *Diabetologia* 1991; 34: 655-661.
119. Anatomia patologica dell'apparato urinario. In *Anatomia patologica clinica*, a cura di Raso M. Piccin Editore Padova 1981; (vol 2): 306.
120. Bloodworth JMB Jr. A re-evaluation of diabetic glomerulosclerosis 50 years after the discovery of insulin. *Human Pathol* 1978; 9: 439-453.
121. Viberti G, Keen H. The patterns of proteinuria in diabetes mellitus. Relevance to pathogenesis and prevention of diabetic nephropathy. *Diabetes* 1984; 33: 686-692.
122. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient?. *Diabetes* 2000; 49: 1399-1408.
123. Penno G, Pucci L, Lucchesi D, *et al.* Diagnostica di laboratorio: esami su urine. *Gli esami per il diabete*. *Riv Med Lab-JLM* 2002; 1 (vol 3): 44-53.
124. Caramori ML, Mauer M. Diabetic nephropathy. In Greenberg A ed: *Primer on kidney diseases*. 3rd edition. New York, National Kidney Foundation 2001; 28: 212-218.

125. Rachmani R, Levi Z, Lidar M, *et al.* Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: lessons from an 8-year follow-up study of 599 patients. *Diabetes Res Clin Pract* 2000; 49: 187-194.
126. Lurbe E, Redon J, Kesani A, *et al.* Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. *N Engl J Med* 2002; 347: 797-805.
127. Nakano S, Ogihara M, Tamura C, *et al.* Reversed circadian blood pressure rhythm independently predicts endstage renal failure in non-insulin-dependent diabetes mellitus subjects. *J Diabetes Complications* 1999; 13: 224-231.
128. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. *N Engl J Med* 2002; 346: 1145-1151.
129. Gross JL, de Azevedo MJ, Silveiro SP, *et al.* Diabetic nephropathy: diagnosis, prevention and treatment. *Diabetes Care* 2005; 28: 164-176.
130. The Diabetes Control and Complications Trial Research Group. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. *N Engl J Med* 1993; 329: 977-986.
131. Sacks DB, Bruns DE, Goldstein DE, *et al.* Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. *Clinical Chemistry* 2002; 48: 436-472.
132. Reach G. Continuous glucose monitoring and diabetes health outcomes: a critical appraisal. *Diabetes Technol Ther* 2008; 10: 69-80.
133. Halford J, Harris C. Determining clinical and psychological benefits and barriers with continuous glucose monitoring therapy. *Diabetes Technol Ther* 2010; 12: 201-205.
134. McGarraugh G. The chemistry of commercial continuous glucose monitors. *Diabetes Technology & Therapeutics* 2009; 11: S17-S24.
135. Keenan DB, Mastrototaro JJ, Voskanyan G, *et al.* Delays in Minimally Invasive Continuous Glucose Monitoring Devices: A Review of Current Technology. *J of Diabetes Science and Technology* 2009; 5 (vol 3): 1207-1214.
136. Nathan DM, Kuenen J, Borg R, *et al.* Translating the A1C assay into estimated average glucose values. *Diabetes Care* 2008; 31: 1473-1478.
137. [No authors listed]. Executive Summary: standards of medical care in diabetes-2009. *Diabetes Care* 2009; 32: S6-S12.

138. Mayfield J, Havas S. Self-control: a physician's guide to blood glucose monitoring in the management of diabetes. Leawood, KS: American Academy of Family Physicians 2004.
139. Chobanian AV, Bakris GL, Black HR, *et al.* Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension* 2003; 42: 1206-1252.
140. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. *Ann Intern Med* 2001; 134: 370-379.
141. Barnett AH, Bain SC, Bouter P, *et al.* Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. *N Engl J Med* 2004; 351: 1952-1961.
142. Lewis EJ, Hunsicker LG, Clarke WR, *et al.* Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* 2001; 345: 851-860.
143. Brenner BM, Cooper ME, de Zeeuw D, *et al.* Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001; 345: 861-869.
144. Parving HH, Lehnert H, Bröchner-Mortensen J, *et al.* The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med* 2001; 345: 870-878.
145. Rossing K, Jacobsen P, Pietraszek L, *et al.* Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. *Diabetes Care* 2003; 26: 2268-2274.
146. Weinberg AJ, Zappe DH, Ashton M, *et al.* Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. *Am J Nephrol* 2004; 24: 340-345.
147. Rossing K, Schjoedt KJ, Jensen BR, *et al.* Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. *Kidney Int* 2005; 68: 1190-1198.
148. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. *J Clin Invest* 2006; 116: 288-296.

149. Schjoedt KJ, Andersen S, Rossing P, *et al.* Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. *Diabetologia* 2004; 47: 1936-1939.
150. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. *J Clin Invest* 1996; 15: 1063-1068.
151. Sato A, Hayashi K, Naruse M, *et al.* Effectiveness of aldosterone blockade in patients with diabetic nephropathy. *Hypertension* 2003; 41: 64-68.
152. Fioretto P, Steffes MW, Sutherland DE, *et al.* Reversal of lesions of diabetic nephropathy after pancreas transplantation. *N Engl J Med* 1998; 339: 69-75.
153. Solassol J, Jacot W, Lhermitte L, *et al.* Clinical proteomics and mass spectrometry profiling for cancer detection. *Expert Rev Proteomics* 2006; 3: 311-320.
154. Peng J, Gygi SP. Proteomics: the move to mixtures. *J Mass Spectrom* 2001; 36: 1083-1091.
155. Tolson JP, Flad T, Gnau V, *et al.* Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. *Proteomics* 2006; 6: 697-708.
156. Wilkins MR, Sanchez JC, Gooley AA, *et al.* Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. *Biotechnol Genet Eng Rev* 1996; 13: 19-50.
157. De Noo ME, Tollenaar RA, Ozalp A, *et al.* Reliability of human serum protein profiles generated with C8 magnetic beads assisted MALDI-TOF Mass Spectrometry. *Analytical Chemistry* 2005; 77: 7232-7241.
158. Aebersold R, Mann M. Mass spectrometry-based proteomics. *Nature* 2003; 422: 198-207.
159. MacNeil JS. Better biomarkers for the diagnostics labyrinth. *Genome Technol* 2004; 24-33.
160. Nyman TA. The role of mass spectrometry in proteome studies. *Biomol Eng* 2001; 18: 221-227.
161. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. *Nature* 2004; 431: 931-945.
162. Purohit S, Podolsky R, Schatz D, *et al.* Assessing the utility of SELDI-TOF and model averaging for serum proteomic biomarker discovery. *Proteomics* 2006; 6: 6405-6415.

163. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. *Molecular & Cellular Proteomics* 2004; 3: 367-378.
164. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. *Journal Biol Chem* 1975; 250: 4007-4021.
165. Corti V, Cattaneo A, Bachi A, *et al.* Identification of grass pollen allergens by two-dimensional gel electrophoresis and serological screening. *Proteomics* 2005; 5: 729-736.
166. Ye B, Skates S, Mok SC, *et al.* Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. *Clinical Cancer Research* 2006; 12: 432-441.
167. Lopez JL. Two-dimensional electrophoresis in proteome expression analysis. *J Chromatogr B Analyt Technol Biomed Life Sci* 2007; 849: 190-202.
168. Weissinger EM, Wittke S, Kaiser T, *et al.* Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. *Kidney Int* 2004; 65: 2426-2434.
169. Wulfkühle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. *Nature Rev. Cancer* 2003; 3: 267-275.
170. Latterich M, Abramovitz M, Leyland-Jones B. Proteomics: New technologies and clinical applications. *Eur J Cancer* 2008; 44: 2737-41.
171. Turecek F. Mass spectrometry in coupling with affinity capture-release and isotope-coded affinity tags for quantitative protein analysis. *J Mass Spectrom* 2002; 37: 1-14.
172. Baltaci S, Aksoy H, Türkölmez K, *et al.* Use of percent free prostate-specific antigen density to improve the specificity for detecting prostate cancer in patients with normal rectal examinations and intermediate prostate-specific antigen levels. *Urol Int* 2003; 70: 36-41.
173. Landers KA, Burger MJ, Tebay MA, *et al.* Use of multiple biomarkers for a molecular diagnosis of prostate cancer. *Int J Cancer* 2005; 114: 950-956.
174. Zhang Z, Barnhill SD, Zhang H, *et al.* Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. *Gynecol Oncol* 1999; 73: 56-61.
175. Pan S, Aebersold R, Chen R, *et al.* Mass Spectrometry Based Targeted Protein Quantification: Methods and Applications. *J Proteome Res* 2009; 8: 787-797.

176. Poon TC. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. *Expert Review of Proteomics* 2007 Feb; 4: 51-65.
177. Koopmann J, Zhang Z, White N, *et al.* Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. *Clinical Cancer Research* 2004; 10: 860-868.
178. Simpkins F, Czechowicz JA, Liotta L, *et al.* SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics. *Pharmacogenomics* 2005; 6: 647-653.
179. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. *Current Opinion in Biotechnology* 2004; 15: 24-30.
180. Diamandis EP. Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics?. *Clin Chem* 2003; 49: 1272-1275.
181. Petricoin III EF, Ardekani AM, Hitt BA, *et al.* Use of proteomic patterns in serum to identify ovarian cancer. *Lancet* 2002; 359: 572-575.
182. Conrads TP, Fusaro VA, Ross S, *et al.* High-resolution serum proteomic features for ovarian cancer detection. *Endocr Relat Cancer* 2004; 11: 163-178.
183. Zhang Z, Bast RC Jr, Yu Y, *et al.* Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. *Cancer Research* 2004; 64: 5882-5890.
184. Lin YW, Lin CY, Lai HC, *et al.* Plasma proteomic pattern as biomarkers for ovarian cancer. *Int J Gynecol Cancer* 2006; 16: 139-146.
185. Villanueva J, Shaffer DR, Philip J, *et al.* Differential exoprotease activities confer tumor-specific serum peptidome patterns. *J Clin Invest* 2006; 116: 271-284.
186. Malik G, Ward MD, Gupta SK, *et al.* Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. *Clinical Cancer Research* 2005; 11: 1073-1085.
187. Boguski MS, McIntosh MW. Biomedical informatics for proteomics. *Nature* 2003; 422: 233-237.
188. Karsan A, Eigl BJ, Flibotte S, *et al.* Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. *Clinical Chemistry* 2005; 51: 1525-1528.
189. Papale M, Pedicillo MC, Thatcher BJ, *et al.* Urine profiling by SELDI-TOF/MS: Monitoring of the critical steps in sample collection, handling and analysis. *J Chromatogr B Analyt Technol Biomed Life Sciences* 2007; 856: 205-213.

190. Baumann S, Ceglarek U, Fiedler GM, *et al.* Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *Clinical Chemistry* 2005; 51: 973-980.
191. Powell K. Proteomics delivers on promise of cancer biomarkers. *Nat Med* 2003; 9: 980.
192. Service RF. Public projects gear up to chart the protein landscape. *Science* 2003; 302: 1316-1318.
193. Schwamborn K, Krieg RC, Grosse J, *et al.* Serum Proteomic Profiling in Patients with Bladder Cancer. *Eur Urol* 2009; 56: 989–997.
194. Cheng AJ, Chen LC, Chien KY, *et al.* Oral cancer plasma tumor marker identified with bead-based affinity fractionated proteomic technology. *Clin Chem* 2005; 51: 2236-2244.
195. Villanueva J, Philip J, Entenberg D, *et al.* Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. *Analytical Chemistry* 2004; 76: 1560-1570.
196. Ahmed N, Barker G, Oliva K, *et al.* An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. *Proteomics* 2003; 3: 1980-1987.
197. Zhang X, Leung SM, Morris CR, *et al.* Evaluation of a novel, integrated approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with prestructured sample supports, and pattern recognition software for profiling potential biomarkers in human plasma. *J of Biomolecular Techniques* 2004; 15: 167-175.
198. Chang JT, Chen LC, Wei SY, *et al.* Increase diagnostic efficacy by combined use of fingerprint markers in mass spectrometry--plasma peptidomes from nasopharyngeal cancer patients for example. *Clinical Biochemistry* 2006; 39: 1144-1151.
199. De Noo ME, Mertens BJ, Ozalp A, *et al.* Detection of colorectal cancer using MALDI-TOF serum protein profiling. *European Journal of Cancer* 2006; 42: 1068-1076.
200. Thomson JJ. Ray of positive electricity and their application to chemical analyses. London, Longmans Green and Co 1913.
201. Aston FW. A positive ray spectrograph. *Phil Mag* 1919; 38: 707-714.

202. Aston FW. The mass-spectra of chemical elements. *Phil Mag* 1920; 39: 611-625.
203. Aston FW. Mass spectra and atomic weight. *J Chem Soc* 1921; 119: 677-687.
204. Müller DR, Schindler P, Coulot M, *et al.* Mass spectrometric characterization of stathmin isoforms separated by 2D PAGE. *J Mass Spectrom* 1999; 34: 336-345.
205. Yates JR. Mass spectrometry and the age of the proteome. *J Mass Spectrom* 1998; 33: 1-19.
206. Tanaka K, Waki H, Ido Y, *et al.* Protein and Polymer Analyses up to m/z 100 000 by Laser Ionization Time-of-flight Mass Spectrometry. *Rapid Commun Mass Spectrom* 1988; 2: 151-153.
207. Fenn JB, Mann M, Meng CK, *et al.* Electrospray ionization for mass spectrometry of large biomolecules. *Science* 1989; 246: 64-71.
208. Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. *Anal Chem* 1988; 60: 2299-2301.
209. Hillenkamp F, Karas M, Beavis RC, *et al.* Matrix-assisted laser desorption/ionization mass spectrometry of biopolymers. *Anal Chem* 1991; 63: 1193A-1203A.
210. Katta V, Chow DT, Rohde MF. Applications of in-source fragmentation of protein ions for direct sequence analysis by delayed extraction MALDI-TOF mass spectrometry. *Anal Chem* 1998; 70: 4410-4416.
211. Barber M, Bordoli RS, Sedgwick RD, *et al.* Fast atom bombardment mass spectrometry of bleomycin A2 and B2 and their metal complexes. *Biochem Biophys Res Commun* 1981; 101: 632-638.
212. Glückmann M, Karas M. The initial ion velocity and its dependence on matrix, analyte and preparation method in ultraviolet matrix-assisted laser desorption/ionization. *J Mass Spectrom* 1999; 34: 467-477.
213. Bakhtiar R, Nelson RW. Electrospray ionization and matrix-assisted laser desorption ionization mass spectrometry. *Emerging technologies in biomedical sciences. Biochem Pharmacol* 2000; 59: 891-905.
214. Jonscher KR, Yates JR. The quadrupole ion trap mass spectrometer—a small solution to a big challenge. *Anal Biochem* 1997; 244: 1-15.
215. Marshall A. Fourier transform ion cyclotron resonance detection: principles and experimental configurations. *International J of Mass Spectrometry* 2002; 215: 59.

216. Shen Y, Smith RD. Advanced nanoscale separations and mass spectrometry for sensitive high-throughput proteomics. *Expert Rev Proteomics* 2005; 2: 431-447.
217. Posthumus MA, Kistemaker PG, Meuzelaar HLC *et al.* Laser desorption-mass spectrometry of polar nonvolatile bio-organic molecules. *Anal Chem* 1978; 50: 985-991.
218. Marvin LF, Roberts MA, Fay LB. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in clinical chemistry. *Clinical Chim Acta* 2003; 337: 11-21.
219. Wittal RM, Li L. High resolution matrix-assisted laser desorption/ionization in a linear time-of-flight mass spectrometer. *Anal Chem* 1995; 67: 1950-1954.
220. Beavis RC, Chait BT. High-accuracy molecular mass determination of proteins using matrix-assisted laser desorption mass spectrometry. *Anal Chem* 1990; 62: 1836-1840.
221. Zenobi R, Knochenmuss R. Ion formation in MALDI mass spectrometry. *Mass Spectrom Reviews* 1998; 17: 337-366.
222. Karas M, Bahr U, Strupat K, *et al.* Matrix dependence of metastable fragmentation of glycoproteins in MALDI TOF mass spectrometry. *Anal Chem* 1995; 67: 675-679.
223. Cotter RJ. Time-of-flight mass spectrometry: an increasing role in the life sciences. *Biomed Environ Mass Spectrom* 1989; 18: 513-532.
224. Katta V, Chow DT, Rohde MF. Application of In-Source fragmentation of Protein Ions for Direct Sequence Analysis by Delayed Extraction MALDI-TOF Mass Spectrometry. *Anal Chem* 1998; 70: 4410-4416.
225. Chaurand P, Luetzenkirchen F, Spengler B. Peptide and protein identification by matrix-assisted laser desorption ionization (MALDI) and MALDI-post-source decay time-of-flight mass spectrometry. *J Am Soc Mass Spectrom* 1999; 10: 91-103.
226. Hoffmann R, Metzger S, Spengler B, *et al.* Sequencing of peptides phosphorylated on serines and threonines by post-source decay in matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *J Mass Spectrom* 1999; 34: 1195-1204.
227. Lee ED, Muck W, Henion JD, *et al.* On-line capillary zone electrophoresis-ion spray tandem mass spectrometry for the determination of dynorphins. *J Chromatogr* 1988; 458: 313-321.

228. Wilm M, Mann M. Analytical properties of the nanoelectrospray ion source. *Anal Chem* 1996; 68: 1-8.
229. Wilm M, Sheychenko A, Houthaeve T, *et al.* Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry. *Nature* 1996; 379: 466-469.
230. Dooley KC. Tandem mass spectrometry in the clinical chemistry laboratory. *Clinical Biochemistry* 2003; 36: 471-481.
231. Yates JR, McCormack AL, Eng J. Mining genomes with MS. *Anal Chem* 1996; 68: 534-540.
232. Steen H, Mann M. The ABC's (and XYZ's) of peptide sequencing. *Nat Rev Mol Cell Biol* 2004; 5: 699-711.
233. Bosso N, Chinello C, Picozzi SCM, *et al.* Human urine biomarkers of renal cell carcinoma evaluated by ClinProt. *Proteomics Clin Appl* 2008; 2: 1036-1046.
234. Swets JA. Measuring the accuracy of diagnostic systems. *Science* 1988; 240: 1285-1293.
235. Pappin DJ, Hojrup P, Bleasby AJ. Rapid identification of proteins by peptide-mass fingerprinting. *Curr Biol* 1993; 3: 327-332.
236. Chinello C, Gianazza E, Zoppis I, *et al.* Serum biomarkers of renal cell carcinoma assessed using a protein profiling approach based on clinprot technique. *Urology* 2010; 75: 842-847.
237. Gianazza E, Mainini V, Castoldi G, *et al.* Different expression of fibrinopeptide A and related fragments in serum of type 1 diabetic patients with nephropathy. *J of Proteomics* 2010; 73: 593-601.
238. Molitch ME, DeFronzo RA, Franz MJ, *et al.* Nephropathy in diabetes. *Diabetes Care* 2004; 27: S79-S83.
239. Cairns DA, Barrett JH, Billingham LJ, *et al.* Sample size determination in clinical proteomic profiling experiments using mass spectrometry for class comparison. *Proteomics* 2009; 9: 74-86.
240. Magni F, Sarto C, *et al.* Expanding the proteome two-dimensional gel electrophoresis reference map of human renal cortex by peptide mass fingerprinting. *Proteomics* 2005; 5: 816-825.
241. Pieper R, Gatlin CL, McGrath AM, *et al.* Characterization of the human urinary proteome: A method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. *Proteomics* 2004; 4: 1159-1174.

242. Sarto C, Proserpio V, *et al.* Insight on renal cell carcinoma proteome. In Sayed DS, ed: Cancer Proteomics. From Bench to Bedside. Totowa, NJ, Humana Press 2008; 121-137.
243. Ticozzi-Valerio D, Raimondo F, *et al.* Differential expression of AQP1 in microdomain-enriched membranes of renal cell carcinoma. *Proteomics Clin Appl* 2007; 1: 588-597.
244. Dallmann K, Junker H, *et al.* Human agmatinase is diminished in the clear cell type of renal cell carcinoma. *Int J Cancer* 2004; 108: 342-347.
245. Von Eggeling F, Junker K, Fiedle W, *et al.* Mass spectrometry meets chip technology: A new proteomic tool in cancer research?. *Electrophoresis* 2001; 22: 2898-2902.
246. Rogers MA, Clarke P, Noble J, *et al.* Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting clinical utility. *Cancer Res* 2003; 63: 6971-6983.
247. Hara T, Honda K, *et al.* Identification of 2 serum biomarkers of renal cell carcinoma by surface enhanced laser desorption/ ionization mass spectrometry. *J Urol* 2005; 174: 1213-1217.
248. Ebert MPA, Niemeyer D, *et al.* Identification and confirmation of increased fibrinopeptide A serum protein levels in gastric cancer sera by magnet bead assisted MALDI-TOF mass spectrometry. *J Proteome Res* 2006; 5: 2152-2158.
249. Balog CI, Hensbergen PJ, Derks R, *et al.* Novel Automated Biomarker Discovery Work Flow for Urinary Peptidomics. *Clin Chem* 2009; 55: 117-25.
250. Mischak H, Kaiser T, *et al.* Proteomic analysis for the assessment of diabetic renal damage in humans. *Clin Sci (Lond)* 2004; 107: 485-495.
251. Bellei E, Rossi E, *et al.* Proteomic analysis of early urinary biomarkers of renal changes in type 2 diabetic patients. *Proteomics Clin Appl* 2008; 2: 478-491.
252. Jiang H, Guan G, *et al.* Identification of urinary soluble E-cadherin as a novel biomarker for diabetic nephropathy. *Diabetes Metab Res Rev* 2009; 25: 232-241.
253. Rossing K, Mischak H, *et al.* Urinary proteomics in diabetes and CKD. *J Am Soc Nephrol* 2008; 19: 1283-1290.
254. Timms JF, Arslan-Low E, Gentry-Maharaj A, *et al.* Preanalytic influence of sample handling on SELDI-TOF serum protein profiles. *Clin Chem* 2007; 53: 645-656.

255. Hsieh SY, Chen RK, Pan YH, *et al.* Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum/plasma proteome profiling. *Proteomics* 2006; 6: 3189-3198.
256. Sundsten T, Eberhardson M, Goransson M, *et al.* The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes. *Proteome Sci* 2006; 4: 22.
257. Meier M, Kaiser T, Herrmann A, *et al.* Identification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis. *J Diabetes Complicat* 2005; 19: 223-232.
258. Snell-Bergeon JK, Maahs DM, Ogden LG, *et al.* Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease. *Diabetes Technol Ther* 2009; 11: 1-9.
259. Albrethsen J, Kaas A, Schonle E, *et al.* Evaluation of a type 1 diabetes serum cohort by SELDI-TOF MS protein profiling. *Proteomics Clin Appl* 2009; 3: 383-393.
260. Alkjaersig N, Fletcher AP. Catabolism and Excretion of Fibrinopeptide A. *Blood* 1982; 60: 148-156.
261. Sporn LA, Bunce LA, Francis CW. Cell proliferation on fibrin: modulation by fibrinopeptide cleavage. *Blood* 1995; 86:1802-10.
262. Mosesson MW. Fibrinogen and fibrin structure and functions. *J Thrombosis Haemostasis* 2005; 3: 1894-1904.
263. Kaizu K, Uriu K, Hashimoto O, *et al.* Role of intrarenal coagulation and anticoagulant therapy in the progression of diabetic nephropathy. *Nippon Jinzo Gakkai Shi* 1993; 35: 35-42.
264. Herrick S, Blanc-Brude O, Gray A, *et al.* Fibrinogen. *International J Biochem Cell Biology* 1999; 31: 741-746.
265. Orvisky E, Drake SK, Hortin GL, *et al.* Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma. *Proteomics* 2006; 6: 2895-2902.
266. Theodorescu D, Wittke S, Ross MM, *et al.* Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. *Lancet Oncology* 2006; 7: 230-240.
267. Jones RL. Fibrinopeptide A in diabetes mellitus. Relation to levels of blood glucose, fibrinogen disappearance and hemodynamic changes. *Diabetes* 1985; 34: 836-843.

268. Ceriello A, Giacomello R, Stel G, *et al.* Hyperglycemia may determine fibrinopeptide A plasma level increase in humans. *Metabolism* 1989; 38: 1162-1163.
269. Nomura F, Takahashi N, Inami N, *et al.* Identification of novel and downregulated biomarkers for alcoholism by surface enhanced laser desorption/ionization-mass spectrometry. *Proteomics* 2004; 4: 1187-1194.
270. Villanueva J, Philip J, Chaparro CA, *et al.* Differential exoprotease activities confer tumor-specific serum peptidome patterns. *J Clin Invest* 2006; 116: 271-284.
271. Meigs JB, D'Agostino RB, Wilso OW, *et al.* Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. *Diabetes* 1997; 46: 1594-1600.
272. Tessari P, Kiwanuka R, Barazzoni M, *et al.* Diabetic nephropathy is associated with increased albumin and fibrinogen production in patients with type 2 diabetes. *Diabetologia* 2006; 49: 1955-1961.
273. Le DS, Miles R, Savage PJ, *et al.* The association of plasma fibrinogen concentration with diabetic microvascular complications in young adults with early-onset of type 2 diabetes. *Diabetes Res Clin Pract* 2008; 82: 317-323.
274. Lengyel Z, *et al.* Urinary albumin excretion is correlated to fibrinogen levels and protein S activity in patients with type 1 diabetes mellitus without overt diabetic nephropathy. *Wien Klein Wochenschr* 2004; 116: 240-245.
275. Harmanci A, Kandemir N, Dagdelen S, *et al.* Thrombin-activatable fibrinolysis inhibitor activity and global fibrinolytic capacity in Type 1 diabetes: evidence for normal fibrinolytic state. *J Diabetes Complicat* 2006; 20: 40-44.
276. Ward DG, Suggett N, Cheng Y, *et al.* Identification of serum biomarkers for colon cancer by proteomic analysis. *Br J Cancer* 2006; 94: 1898-1905.
277. Lee IN, Chen CH, Sheu JC, *et al.* Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. *Proteomics* 2006; 6: 2865-2873.
278. Miguet L, Bogumil R, Decloquement P, *et al.* Discovery and identification of potential biomarkers in a prospective study of chronic lymphoid malignancies using SELDI-TOF-MS. *J Proteome Res* 2006; 5: 2258-2269.